A carregar...
Association of Optimal Implementation of Sodium-Glucose Cotransporter 2 Inhibitor Therapy With Outcome for Patients With Heart Failure
IMPORTANCE: Sodium-glucose cotransporter 2 inhibitor (SGLT2-i) therapy provided incremental survival benefit to patients with heart failure and reduced ejection fraction (HFrEF) who received guideline-directed medical therapy regardless of type 2 diabetes status in a recent clinical trial. To date,...
Na minha lista:
| Publicado no: | JAMA Cardiol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Medical Association
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7203666/ https://ncbi.nlm.nih.gov/pubmed/32374344 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamacardio.2020.0898 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|